<DOC>
	<DOCNO>NCT01386619</DOCNO>
	<brief_summary>This phase I/II study highly select donor lymphocyte infusion patient undergo HLA-haploidentical hemopoietic stem cell transplantation . Patients offer `` pre-emptive '' NK-DLI early HSCT . Three schedule NK-cell infusion study : Basel patient ( adult pediatric ) receive NK-DLI day +40 +100 ( pre-emptive-late ) ; Frankfurt patient ( pediatric ) receive NK-DLI day +3 , +40 , +100 ( pre-emptive early ) . Patients receive pre-emptive NK-DLI loss donor chimerism evidence minimal residual disease offer `` therapeutic '' NK-DLI .</brief_summary>
	<brief_title>NK DLI Patients After Human Leukocyte Antigen ( HLA ) -Haploidentical Hematopoietic Stem Cell Transplantation ( HSCT )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients acute/chronic leukemia , myelodysplastic syndrome , lymphoid neoplasia , solid tumor bone marrow failure syndrome sign informed consent patient ( his/her legal representative ) Patients graft failure Patients grade active acute chronic graftversushost disease ( GvHD )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>